

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司 SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON BUSINESS DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that, recently, the Ministry of Industry and Information Technology of China has announced the “List of 2022 Smart Manufacturing Demonstration Factory Results by Enterprises and Excellent Scenario” (2022年度智能製造示範工廠揭榜單位和優秀場景名單), and the “Digital Research and Development and Design of Products” of Shijiazhuang No. 4 Pharmaceutical Co., Ltd., a wholly-owned subsidiary in the Group, has been selected into the “List of 2022 Smart Manufacturing Excellent Scenario” (2022年度智能製造優秀場景名單) (the “Selection”).

This appraisal was a pilot and demonstration action for 2022 Smart Manufacturing jointly launched by the Ministry of Industry and Information Technology, the National Development and Reform Commission, the Ministry of Finance and the State Administration for Market Regulation of China for the purpose of implementing the Smart Manufacturing Development Plan under the “14th Five-Year Plan” (“十四五”智能製造發展規劃).

The Group has been making continuous and coordinated efforts to push forward the research and development of featured generic drugs, bulk pharmaceuticals, innovative drugs, medical materials as well as product types under consistency evaluation by using market demands as the guide and adhering to the strategy of “combination of generic and innovative drugs” in order to solidify and expand its strength in the research, development and manufacturing of featured generic drugs. The Company believes that the Selection is a recognition to the Group’s research and development capability, and expects that the Selection will help promoting future development of the Group’s business in research and development of pharmaceutical products.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 4 January 2023

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo and Mr. Chow Hing Yeung as executive Directors, Mr. Feng Hao as non-executive Director and Mr. Wang Yibing, Mr. Leung Chong Shun, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.